share_log

Stifel Maintains Buy on Verve Therapeutics, Lowers Price Target to $40

Stifel Maintains Buy on Verve Therapeutics, Lowers Price Target to $40

Stifel维持对Verve Therapeutics的买入,将目标股价下调至40美元
Moomoo 24/7 ·  04/03 08:47

Stifel analyst Dae Gon Ha maintains Verve Therapeutics (NASDAQ:VERV) with a Buy and lowers the price target from $56 to $40.

Stifel分析师Dae Gon Ha维持Verve Therapeutics(纳斯达克股票代码:VERV)的买入并将目标股价从56美元下调至40美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发